Lassalle P, Gosset P, Delneste Y, Tsicopoulos A, Capron A, Joseph M, Tonnel A B
INSERM CJF no. 90-06, Institut Pasteur, Lille, France.
Clin Exp Immunol. 1993 Oct;94(1):105-10. doi: 10.1111/j.1365-2249.1993.tb05985.x.
In a previous work we have demonstrated that in patients exhibiting a late allergic reaction (LAR), alveolar macrophages (AM) collected 18 h after bronchial allergen challenge produced high levels of IL-6 and tumour necrosis factor-alpha (TNF) which is known to up-regulate the endothelial cell expression of adhesion molecules participating in the development of the inflammatory reaction in bronchial asthma. For these reasons, we evaluated the effect of AM supernatants from asthmatic patients developing an LAR on intercellular adhesion molecule-1 (ICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) expression by human endothelial cells. The expression of adhesion molecules was assessed by an ELISA method and compared with the effect of an optimal dose of human recombinant (hr) TNF. Results showed that AM supernatants, from challenged asthmatics developing an LAR, increased significantly the ICAM-1 and ELAM-1 expression on endothelial cells to a level similar to that obtained in the presence of hrTNF (500 U/ml) (P < 0.001 in both cases, respectively 90.4% and 75.2% of the level obtained with hrTNF). In contrast, AM supernatants from asthmatics at baseline or exhibiting, after challenge, a single early reaction had no significant effect on these parameters (P = NS in both cases, respectively 23.5% and 24.7% of the ICAM-1 expression, 22.7% and 15.3% of the ELAM-1 expression obtained with hrTNF). AM-derived TNF present in these supernatants was thought to play a key role in endothelial cell stimulation, since: (i) TNF concentration in AM supernatants correlated with its effect on ICAM-1 (r = 0.80, P < 10(-4)) and ELAM-1 expression (r = 0.88, P < 10(-5)); and (ii) a neutralizing anti-TNF antibody decreased their effect (68% and 80% respectively on ICAM-1 and ELAM-1 expression). Moreover, the role of IL-6 was excluded on the basis both of the hrIL-6 inefficiency to induce ICAM-1 and ELAM-1 synthesis, even in costimulation with hrTNF, and of anti-IL-6 antibody to neutralize the effect of AM supernatants. Our results suggest that, beside mast cells and lymphocytes, macrophages might participate in the induction of the local inflammatory reaction observed in bronchial asthma. During the LAR, cytokines and especially TNF are able, through an enhanced adhesion molecule expression on endothelial cells, to facilitate the bronchial cellular influx.
在之前的一项研究中,我们已经证明,在出现迟发型过敏反应(LAR)的患者中,支气管过敏原激发后18小时收集的肺泡巨噬细胞(AM)产生高水平的白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF),已知TNF可上调参与支气管哮喘炎症反应发展的黏附分子在内皮细胞上的表达。基于这些原因,我们评估了发生LAR的哮喘患者的AM上清液对人内皮细胞细胞间黏附分子-1(ICAM-1)和内皮白细胞黏附分子-1(ELAM-1)表达的影响。通过酶联免疫吸附测定法(ELISA)评估黏附分子的表达,并与最佳剂量的人重组(hr)TNF的作用进行比较。结果显示,来自发生LAR的激发后哮喘患者的AM上清液显著增加了内皮细胞上ICAM-1和ELAM-1的表达,达到与存在hrTNF(500 U/ml)时相似的水平(两种情况下P均<0.001,分别为hrTNF所获水平的90.4%和75.2%)。相比之下,基线时或激发后出现单一早期反应的哮喘患者的AM上清液对这些参数无显著影响(两种情况下P=无显著性差异,分别为hrTNF所获ICAM-1表达的23.5%和24.7%,ELAM-1表达的22.7%和15.3%)。这些上清液中存在的AM衍生的TNF被认为在内皮细胞刺激中起关键作用,因为:(i)AM上清液中的TNF浓度与其对ICAM-1(r=0.80,P<10⁻⁴)和ELAM-1表达(r=0.88,P<10⁻⁵)的作用相关;(ii)一种中和抗TNF抗体降低了它们的作用(对ICAM-1和ELAM-1表达分别降低68%和80%)。此外,基于hrIL-6即使在与hrTNF共刺激时诱导ICAM-1和ELAM-1合成的无效性以及抗IL-6抗体中和AM上清液作用的情况,排除了IL-6的作用。我们的结果表明,除肥大细胞和淋巴细胞外,巨噬细胞可能参与支气管哮喘中观察到的局部炎症反应的诱导。在LAR期间,细胞因子尤其是TNF能够通过增强内皮细胞上黏附分子的表达来促进支气管细胞流入。